Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

1.

Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement) [Internet].

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

London: National Institute for Health and Clinical Excellence (UK); 2009 May.

2.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

PMID:
20646668
[PubMed - indexed for MEDLINE]
Free Article
3.

The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.

Garg SK.

Diabetes Technol Ther. 2010 Jan;12(1):11-24. doi: 10.1089/dia.2009.0127. Review.

PMID:
20082581
[PubMed - indexed for MEDLINE]
4.

[Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].

Ohsugi M.

Nihon Rinsho. 2011 May;69(5):895-901. Review. Japanese.

PMID:
21595278
[PubMed - indexed for MEDLINE]
5.

Diabetes mellitus: new drugs for a new epidemic.

Nicholson G, Hall GM.

Br J Anaesth. 2011 Jul;107(1):65-73. doi: 10.1093/bja/aer120. Epub 2011 May 24. Review.

PMID:
21610015
[PubMed - indexed for MEDLINE]
Free Article
6.

New treatments in type 2 diabetes: a focus on the incretin-based therapies.

Barnett AH.

Clin Endocrinol (Oxf). 2009 Mar;70(3):343-53. doi: 10.1111/j.1365-2265.2008.03396.x. Epub 2008 Sep 2. Review.

PMID:
18771570
[PubMed - indexed for MEDLINE]
7.

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.

Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, Waugh N.

Health Technol Assess. 2010 Feb;14(11):iii-iv, xi-xvi, 1-181. doi: 10.3310/hta14110. Review.

PMID:
20223123
[PubMed - indexed for MEDLINE]
Free Article
8.

Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.

Ghatak SB, Patel DS, Shanker N, Srivstava A, Deshpande SS, Panchal SJ.

Curr Diabetes Rev. 2010 Nov;6(6):410-21. Review.

PMID:
20879969
[PubMed - indexed for MEDLINE]
9.

Insulin during pregnancy, labour and delivery.

de Valk HW, Visser GH.

Best Pract Res Clin Obstet Gynaecol. 2011 Feb;25(1):65-76. doi: 10.1016/j.bpobgyn.2010.10.002. Epub 2010 Dec 24. Review.

PMID:
21186142
[PubMed - indexed for MEDLINE]
10.

The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.

Baxter MA.

Acta Diabetol. 2008 Dec;45(4):253-68. doi: 10.1007/s00592-008-0052-9. Epub 2008 Sep 3. Review.

PMID:
18766296
[PubMed - indexed for MEDLINE]
11.

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Tahrani AA, Piya MK, Barnett AH.

Adv Ther. 2009 Mar;26(3):249-62. doi: 10.1007/s12325-009-0014-9. Epub 2009 Mar 27. Review. Erratum in: Adv Ther. 2009 Jul;26(7):736.

PMID:
19330494
[PubMed - indexed for MEDLINE]
12.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
[PubMed - indexed for MEDLINE]
13.

Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons.

Sanches AC, Correr CJ, Venson R, Pontarolo R.

Diabetes Res Clin Pract. 2011 Dec;94(3):333-9. doi: 10.1016/j.diabres.2011.09.001. Epub 2011 Oct 11. Review.

PMID:
21992870
[PubMed - indexed for MEDLINE]
14.

Advances in the treatment of type 2 diabetes mellitus.

Israili ZH.

Am J Ther. 2011 Mar-Apr;18(2):117-52. doi: 10.1097/MJT.0b013e3181afbf51. Review.

PMID:
19834322
[PubMed - indexed for MEDLINE]
15.

New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Abbatecola AM, Maggi S, Paolisso G.

Drugs Aging. 2008;25(11):913-25. doi: 10.2165/0002512-200825110-00002. Review.

PMID:
18947259
[PubMed - indexed for MEDLINE]
16.

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

Ahrén B.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):487-98. doi: 10.1016/j.beem.2009.03.003. Review.

PMID:
19748066
[PubMed - indexed for MEDLINE]
17.

A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.

Barnett A, Allsworth J, Jameson K, Mann R.

Curr Med Res Opin. 2007 Jul;23(7):1493-507. Review.

PMID:
17559747
[PubMed - indexed for MEDLINE]
18.
19.

Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.

Kalra S.

J Assoc Physicians India. 2011 Apr;59:237-45. Review.

PMID:
21755761
[PubMed - indexed for MEDLINE]
20.

New ways of insulin delivery.

Heinemann L.

Int J Clin Pract Suppl. 2011 Feb;(170):31-46. doi: 10.1111/j.1742-1241.2010.02577.x. Review.

PMID:
21323811
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk